Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 330

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Open access
Pillai, Rathi N., Behera, Madhusmita, Owonikoko, Taofeek K., Kamphorst, Alice O., Pakkala, Suchita, Belani, Chandra P., Khuri, Fadlo R., Ahmed, Rafi, Ramalingam, Suresh S. · 2018 · Cancer

Abstract

BACKGROUND: Monoclonal antibodies against programmed cell death protein 1 (PD‐1) and programmed death ligand 1 (PD‐L1) are effective therapies in patients with non‐small cell lung cancer (NSCLC). Herein, the authors performed a systematic review investigating differences in the toxicities of PD‐1 and PD‐L1 inhibitors. METHODS: An electronic literature search was performed of public databases (MEDLINE, Excerpta Medica dataBASE [EMBASE], and Cochrane) and conference proceedings for trials using PD‐1 inhibitors (nivolumab and pembrolizumab) and PD‐L1 inhibitors (atezolizumab, durvalumab, and avelumab) in patients with NSCLC. A formal systematic analysis was conducted with Comprehensive Meta‐Analysis software (version 2.2). Clinical and demographic characteristics, response, and toxicity data were compared between both groups. RESULTS: A total of 23 studies reported between 2013 and 2016 were eligible for analysis. The total number of patients evaluated for toxicities was 3284 patients in the PD‐1 group and 2460 patients in the PD‐L1 group. The baseline patient characteristics of the 2 groups were similar, although there was a trend toward increased squamous histology in the group treated with PD‐L1 (32% vs 25%; P = .6). There was no difference in response rate noted between PD‐1 (19%) and PD‐L1 (18.6%) inhibitors (P = .17). The incidence of overall adverse events (AEs) was comparable between the PD‐1 and PD‐L1 inhibitors (64% [95% confidence interval (95% CI), 63%‐66%] vs 66% [95% CI, 65%‐69%]; P = .8). Fatigue was the most frequently reported AE with both classes of drugs. Patients treated with PD‐1 inhibitors were found to have a slightly increased rate of immune‐related AEs (16% [95% CI, 14%‐17%] vs 11% [95% CI, 10%‐13%]; P = .07) and pneumonitis (4% [95% CI, 3%‐5%] vs 2% [95% CI, 1%‐3%]; P = .01) compared with patients who received PD‐L1 inhibitors. CONCLUSIONS: In this systematic review involving 5744 patients with NSCLC, the toxicity and efficacy profiles of PD‐1 and PD‐L1 inhibitors appear to be similar. Cancer 2018;124:271‐7. © 2017 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.31043

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 330

Metadata

Authors
Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S.
Venue
Cancer
Publisher
Wiley
Published
2017-09-28
Volume
124
Issue
2
Pages
271-277
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2756648224
Cited by
330
References
36
FWCI
14.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.